Federal Circuit Signals Change in Course in “Skinny Label” Saga
As predicted in our October 29th post, Teva sought rehearing en banc of the Federal Circuit’s re-instatement of a $235 million jury verdict against it for induced infringement despite its “skinny label” carve out of the patented use. In the original ruling the Federal Circuit held that Teva was liable for damages during a period…